Skip to content

Seaweed extract, Fucoidan, as a supplement to support the development of muscle strength and function

Efficacy of Fucoidan as a supplement for development of muscle strength and function in a athletic adult population: A double blind randomized parallel trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621001632886
Enrollment
40
Registered
2021-11-29
Start date
2025-09-05
Completion date
2025-10-31
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Nutritional supplements are routinely ingested throughout a training period to maximise exercise-based adaptations. Edible seaweeds (macroalgae) have the potential to provide a rich and sustainable source of macronutrients and micronutrients to the human diet. The recent surge of interest in seaweed is fueled by attention on the bioactive components of seaweed, which have potential applications in the food and nutraceutical industries, with impetus toward the reducing cholesterol and improving blood sugar levels. One candidate bioactive compound of interest is the polysaccharide, Fucoidan. Fucoidans are found in brown seaweeds and the health benefits of Fucoidans have been demonstrated in both human and animal studies where the multiple effects include anti-inflammatory, anti-oxidant, anti-tumour, and immune-modulating properties. Our research group in collaboration with industry leading Fucoidan producers (Marinova Pty Ltd) have shown in a pre-clinical study in mice that a novel Fucoidan blend increased muscle mass. While the animal study evidence does exist for Fucoidan imfluencing muscle health, more human evidence (including mechanistic evidence) is needed to evaluate both the nutritional benefit conferred and the efficacy of Fucoidan on muscle health. Therefore, the aim of this pilot clinical trial is to evaluate the effect of oral supplementation of a Fucoidan blend on exercise endurance, muscle strength, anabolic parameters and lean body mass in healthy human subjects. We hypothesize that fucoidan could be a supplement that increases muscle strength with greater adaptations when consumed in addition to resistance training. Here we propose a study designed to establish whether a novel fucoidan blend can potentiate the adaptation of muscle to a resistance training protocol.

Interventions

A double blind randomized parallel trial, placebo controlled study will be conducted in which male and female subjects who regularly weight train (>2 times a week), will perform 6 weeks of strength training with supplement either Fucoidan (500mg oral tablets, twice daily), or placebo (gelatin filled oral tablets, twice daily). All strength training sessions will be conducted at La Trobe University strength and conditioning gym (Bendigo campus), supervised by qualified exercise physiologists, an

A double blind randomized parallel trial, placebo controlled study will be conducted in which male and female subjects who regularly weight train (>2 times a week), will perform 6 weeks of strength training with supplement either Fucoidan (500mg oral tablets, twice daily), or placebo (gelatin filled oral tablets, twice daily). All strength training sessions will be conducted at La Trobe University strength and conditioning gym (Bendigo campus), supervised by qualified exercise physiologists, and involving 2 x 20 minute sessions per week. These sessions will involve a 5-minute dynamic warm-up at an intensity corresponding to 30-50% of 1RM before completing three sets of ten repetitions @70% of 1RM, 2 minutes between sets (weeks 1–2), eight repetitions @80% of 1RM (weeks 3–4), or six repetitions @85% of 1RM (weeks 5–6). This will require a session time for each participant of 20 min, a total of 40 min for the week. To monitor adherence, we will be monitoring returned pill counts and training session attendance checklists.

Sponsors

La Trobe University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1) Adults between the age of 18-50 without a medical contraindication to exercise 2) 6 months experience with resistance training

Exclusion criteria

1) History of treatment for metabolic disease, cardiovascular disease, 2) Currently have any injuries or medical conditions that prohibit exercise, 2) Are currently taking any prescription medication 3) Are pregnant

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026